BOSTON--Harvard Medical School has signed a $16 million, five-year research alliance with the pharmaceutical company Hoechst Marion Roussel involving bioinformatics and cell function. Harvard will receive the funding to study common mechanisms of cell function that have potential applications to human disease, including apoptosis, cell-cycle regulation, and cell regeneration.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.